The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu2/3 receptor agonist, LY379268, is 5-HT1A dependent

Behavioural Brain Research

Volumn 256, Issue , 2013, Pages 298-304

  Wierońska, Joanna M ^a   Slawinska A ^a   Stachowicz, K ^a   Lason Tyburkiewicz M ^a   Gruca, P ^a   Papp, M ^a   Pilc, A ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

LY379268; Metabotropic glutamate receptors; Schizophrenia

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; AMPHETAMINE; DIZOCILPINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; AMINO ACID; FUSED HETEROCYCLIC RINGS; METABOTROPIC RECEPTOR; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPSYCHOTIC EFFECT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; HEAD TWITCH; LOCOMOTION; MALE; MOUSE; NEGATIVE SYNDROME; NONHUMAN; OPEN FIELD TEST; PATTERN RECOGNITION; POSITIVE SYNDROME; PRIORITY JOURNAL; RAT; SOCIAL INTERACTION; AGONISTS; ANIMAL; COGNITION; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; RECOGNITION; SCHIZOPHRENIA; SOCIAL BEHAVIOR; WISTAR RAT;

AMINO ACIDS; ANIMALS; ANTIPSYCHOTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PIPERAZINES; PYRIDINES; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, METABOTROPIC GLUTAMATE; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SOCIAL BEHAVIOR;

EID: 84883546610     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.08.007     Document Type: Article

References (53)

1. Adams D.H., Kinon B.J., Baygani S., Millen B.A., Velona I., Kollack-Walker S., et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry 2013, 13(May (1)):143.
2. Bubeníková-Valesová V., Votava M., Pálenícek T., Horácek J. The opposite effect of a low and a high dose of serotonin-1A agonist on behavior induced by MK-801. Neuropharmacology 2007, 52(4):1071-1078.
3. Cartmell J., Monn J.A., Schoepp D.D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. Journal of Pharmacology Experimental Therapeutics 1999, 291(1):161-170.
4. Cartmell J., Monn J.A., Schoepp D.D. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl) 2000, 148(4):423-429.
5. Clark M., Johnson B.G., Wright R.A., Monn J.A., Schoepp D.D. Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats. Pharmacology Biochemistry and Behavior 2002, 73(2):339-346.
6. Conn P.J., Lindsley C.W., Jones C.K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharmacological Sciences 2009, 30(1):25-31.
7. Cosi C., Koek W. The putative <> 5-HT(1A) receptor antagonist, WAY 100635, has inverse agonist properties at cloned human 5-HT(1A) receptors. European Journal of Pharmacology 2000, 401(1):9-15.
8. Dere E., Huston J.P., De Souza Silva M.A. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neuroscience & Biobehavioral Reviews 2007, 31(5):673-704.
9. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu) 2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0] hexane-4,6-dicarboxylic acid (LY404039). Journal of Pharmacology and Experimental Therapeutics 2008, 326(1):209-217.
10. Fletcher A., Forster E.A., Bill D.J., Brown G., Cliffe I.A., Hartley J.E., et al. Electrophysiological, biochemical, neurohormonal and behavioral studies with WAY100635, a potent, selective and silent 5-HT1A receptor antagonist. Behavioral Brain Research 1996, 73:337-353.
11. Forster E.A., Cliffe I.A., Bill D.J., Dover G.M., Jones D., Reilly Y., et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. European Journal Pharmacology 1995, 281(1):81-88.
12. Fribourg M., Moreno J.L., Holloway T., Provasi D., Baki L., Mahajan R., et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011, 147(5):1011-1023.
13. Galici R., Echemendia N.G., Rodriguez A.L., Conn P.J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. Journal of Pharmacology and Experimental Therapeutics 2005, 315(3):1181-1187.
14. Galici R., Jones C.K., Hemstapat K., Nong Y., Echemendia N.G., Williams L.C., et al. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. Journal of Pharmacology and Experimental Therapeutics 2006, 318(1):173-185.
15. Gewirtz J.C., Marek G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 2000, 23(5):569-576.
16. González-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., López-Giménez J.F., et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452(7183):93-97.
17. Gu G., Lorrain D.S., Wei H., Cole R.L., Zhang X., Daggett L.P., et al. Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: implication in emotional responses and central disinhibition. Brain Research 2008, 1197:47-62.
18. Hagiwara H., Fujita Y., Ishima T., Kunitachi S., Shirayama Y., Iyo M., et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. European Neuropsychopharmacology 2008, 18(6):448-454.
19. Homberg J.R., De Boer S.F., Raasø H.S., Olivier J.D., Verheul M., Ronken E., et al. Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats. Psychopharmacology (Berl) 2008, 200(3):367-380.
20. Horiguchi M., Hannaway K.E., Adelekun A.E., Jayathilake K., Meltzer H.Y. Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. Neuropsychopharmacology 2012, 37(10):2175-2183.
21. Horiguchi M., Meltzer H.Y. Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT(1A) partial agonism. Behavioral Brain Research 2013, 247:158-164.
22. Horiguchi M., Meltzer H.Y. The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl) 2012, 221(2):205-215.
23. Horiguchi M., Huang M., Meltzer H.Y. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. Journal of Pharmacology and Experimental Therapeutics 2011, 338(2):605-614.
24. Horiguchi M., Huang M., Meltzer H.Y. Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) 2011, 217(1):13-24.
25. Jones C.A., Brown A.M., Auer D.P., Fone K.C. The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology (Berl) 2011, 214(1):269-283.
26. Johnson M.P., Barda D., Britton T.C., Emkey R., Hornback W.J., Jagdmann G.E., et al. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 2005, 179(1):271-283.
27. Kinon B.J., Zhang L., Millen B.A., Osuntokun O.O., Williams J.E., Kollack-Walker S., et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. Journal of Clinical Psychopharmacology 2011, 31(3):349-355.
28. Li Z., Ichikawa J., Dai J., Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. European Journal of Pharmacology 2004, 493(1-3):75-83.
29. Luján R., Roberts J.D., Shigemoto R., Ohishi H., Somogyi P. Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites. Journal of Chemical Neuroanatomy 1997, 13(4):219-241.
30. Matrisciano F., Dong E., Gavin D.P., Nicoletti F., Guidotti A. Activation of group II metabotropic glutamate receptors promotes DNA demethylation in the mouse brain. Molecular Pharmacology 2011, 80(1):174-182.
31. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2003, 27(7):1159-1172.
32. Meltzer H.Y., Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?. Behavioral Brain Research 2008, 195(1):98-102.
33. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281(5381):1349-1352.
34. Nagai T., Murai R., Matsui K., Kamei H., Noda Y., Furukawa H., et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 2009, 202(1-3):315-328.
35. Neki A., Ohishi H., Kaneko T., Shigemoto R., Nakanishi S., Mizuno N. Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: an immunohistochemical study with a monoclonal antibody. Neuroscience Letters 1996, 202(3):197-200.
36. Neki A., Ohishi H., Kaneko T., Shigemoto R., Nakanishi S., Mizuno N. Metabotropic glutamate receptors mGluR2 and mGluR5 are expressed in two non-overlapping populations of Golgi cells in the rat cerebellum. Neuroscience 1996, 75(3):815-826.
37. Ohishi H., Ogawa-Meguro R., Shigemoto R., Kaneko T., Nakanishi S., Mizuno N. Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 and mGluR3, in rat cerebellar cortex. Neuron 1994, 13(1):55-66.
38. Pałucha-Poniewiera A., Kłodzińska A., Stachowicz K., Tokarski K., Hess G., Schann S., et al. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 2008, 55(4):517-524.
39. Palucha A., Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacology Therapeutics 2007, 115(1):116-147.
40. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine 2007, 13(9):1102-1107.
41. Petralia R.S., Wang Y.X., Niedzielski A.S., Wenthold R.J. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 1996, 71(4):949-976.
42. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34(1):1-26.
43. Rorick-Kehn L.M., Johnson B.G., Knitowski K.M., Salhoff C.R., Witkin J.M., Perry K.W., et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 2007, 193(1):121-136.
44. Satow A., Suzuki G., Maehara S., Hikichi H., Murai T., Murai T., et al. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one. Journal of Pharmacology and Experimental Therapeutics 2009, 330(1):179-190.
45. Scorza M.C., Castañé A., Bortolozzi A., Artigas F. Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice. Neuropharmacology 2010, 59(1/2):112-120.
46. Tamaru Y., Nomura S., Mizuno N., Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 2001, 106(3):481-503.
47. Uslaner J.M., Smith S.M., Huszar S.L., Pachmerhiwala R., Hinchliffe R.M., Vardigan J.D., et al. Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. Psychopharmacology (Berl) 2009, 206(November (4)):641-651.
48. van den Buuse M., Gogos A. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition. Journal of Pharmacology and Experimental Therapeutics 2007, 320(3):1224-1236.
49. Wierońska J.M., Stachowicz K., Acher F., Lech T., Pilc A. Opposing efficacy of group III mGlu receptor activators, LSP 1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology (Berl) 2012, 220(3):481-494.
50. Wierońska J.M., Kusek M., Tokarski K., Wabno J., Froestl W., Pilc A. The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice. British Journal of Pharmacology 2011, 163(5):1034-1047.
51. Wierońska J.M., Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochemistry International 2009, 55(1-3):85-97.
52. Wierońska J.M., Acher F.C., Sławińska A., Gruca P., Lasoń-Tyburkiewicz M., Papp M., et al. The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT1A signalling. Psychopharmacology (Berl) 2013, 227(4):711-725.
53. Woolley M.L., Pemberton D.J., Bate S., Corti C., Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008, 196(3):431-440.